Scoop: Med­Im­mune chief Bahi­ja Jal­lal is leav­ing As­traZeneca and join­ing the trek in­to biotech

Six years af­ter As­traZeneca’s then new CEO Pas­cal So­ri­ot named Bahi­ja Jal­lal pres­i­dent of the big Med­Im­mune sub­sidiary in Gaithers­burg, MD, putting her at the cen­ter of the com­pa­ny’s R&D turn­around plans, the long­time phar­ma ex­ec is join­ing the great mi­gra­tion of in­dus­try pro­fes­sion­als to biotech.

Eliot Forster

Jal­lal is tak­ing the helm at Im­muno­core next week, a promi­nent TCR play­er in the UK which has been go­ing through a re­mark­able shake­up af­ter the orig­i­nal team un­der CEO Eliot Forster — now chief at F-star — ei­ther left or were forced out. Im­muno­core was able to raise $320 mil­lion a lit­tle more than 3 years ago — a time when that kind of mon­ey was still able to cause as­ton­ish­ment in the in­dus­try.

This wasn’t the first such biotech job to come along, Jal­lal tells me in an ex­clu­sive in­ter­view ahead of the an­nounce­ment. “But when the right one is there you jump on it.”

The job starts on Mon­day, and Jal­lal says she feels like “a kid in a can­dy store” when it comes to Im­muno­core, a com­pa­ny with a broad plat­form that is built to ac­com­mo­date on­col­o­gy as well as in­fec­tious dis­eases and au­toim­mune con­di­tions.

And Jal­lal isn’t the on­ly se­nior As­traZeneca ex­ec head­ing to new biotech fields. The Wall Street Jour­nal re­ports to­day that Mark Mal­lon — cur­rent EVP in charge of port­fo­lio strat­e­gy — is on his way to take the CEO job at Iron­wood, as that com­pa­ny splits up un­der pres­sure and Pe­ter Hecht leaves to run the R&D spin­out.

An­drew Hotchkiss

Over the past year-plus Im­muno­core has run in­to some se­vere tur­bu­lence af­ter it tried to shop a new round at its old uni­corn val­u­a­tion. Po­ten­tial in­vestors weren’t ready to buy in, trig­ger­ing an ex­o­dus at the top and a move up for chief com­mer­cial of­fi­cer An­drew Hotchkiss as in­ter­im chief.

Jal­lal says Hotchkiss has done a great job this year, which in­cludes ink­ing a ma­jor new pact with Genen­tech, and he’ll go back to con­cen­trat­ing on his com­mer­cial fo­cus with an eye on ad­vanc­ing Im­muno­core’s late-stage can­cer ther­a­py to­ward the mar­ket.

“I can tell you there’s been a lot of progress in the past year,” she adds. “Next week we’re go­ing to JP­Mor­gan and share the sto­ry with the in­vestor com­mu­ni­ty and oth­ers. My in­ten­tion is to bring re­as­sur­ance to in­vestors that I will bring sta­bil­i­ty to the or­ga­ni­za­tion, bring the best team and have the vi­sion we can all work to­geth­er and show them why I am join­ing the com­pa­ny.”

Mene Pan­ga­los

Jal­lal was one of three top R&D ex­ecs So­ri­ot picked for the Big Phar­ma’s turn­around in 2013. Brig­gs Mor­ri­son left sev­er­al years ago to run Syn­dax. That leaves Mene Pan­ga­los and his new col­leagues to run the show at As­traZeneca’s re­search and de­vel­op­ment op­er­a­tions.

There’s no im­me­di­ate word on who will re­place Jal­lal at Med­im­mune, where she steered 5 drugs to an ap­proval, in­clud­ing their check­point play­er Imfinzi.


Im­age: Bahi­ja Jal­lal. MED­IM­MUNE

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA has vowed not to let politics overrule science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped the FDA and other health agencies under his purview of their rule making ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

President Donald Trump (via AP Images)

Signs of an 'Oc­to­ber Vac­cine Sur­prise' alarm ca­reer sci­en­tists

President Donald Trump, who seems intent on announcing a COVID-19 vaccine before Election Day, could legally authorize a vaccine over the objections of experts, officials at the FDA and even vaccine manufacturers, who have pledged not to release any vaccine unless it’s proved safe and effective.

In podcasts, public forums, social media and medical journals, a growing number of prominent health leaders say they fear that Trump — who has repeatedly signaled his desire for the swift approval of a vaccine and his displeasure with perceived delays at the FDA — will take matters into his own hands, running roughshod over the usual regulatory process.

#ES­MO20: Push­ing in­to front­line, Mer­ck and Bris­tol My­ers duke it out with new slate of GI can­cer da­ta

Having worked in parallel for years to move their respective PD-1 inhibitors up to the first-line treatment of gastrointestinal cancers, Merck and Bristol Myers Squibb finally have the data at ESMO for a showdown.

Comparing KEYNOTE-590 and CheckMate-649, of course, comes with the usual caveats. But a side-by-side look at the overall survival numbers also offer some perspective on a new frontier for the reigning checkpoint rivals, both of whom are claiming to have achieved a first.

Frank Zhang (AP Images)

Rocked by cus­toms in­ves­ti­ga­tion, Leg­end's CFO takes over as CEO Frank Zhang placed un­der house ar­rest

When Frank Zhang stepped down from GenScript — the contract research group he’s run for 18 years — to take up the CEO post at its CAR-T focused spinout Legend Biotech, he assured analysts that he was in for the long haul.

Just 49 days later, though, he’s been forced to hand back the title.

In a dramatic turn of events, Legend disclosed that Zhang is under house arrest in China as part of a customs investigation involving GenScript. While he remains the chairman, CFO Ying Huang has been tapped to double as interim CEO.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Two wild weeks for Grail end in $8B Il­lu­mi­na buy­out

Grail’s whirlwind two weeks have ended in the wealthy arms of its former founder and benefactors.

Illumina has shelled out $8 billion to reacquire the closely-watched liquid biopsy startup they spun out just 5 years ago and sold off much of its shares just 3 years ago. The deal comes nearly two weeks after the well-heeled startup filed for a potentially massive IPO — one that was disrupted just a week later when Bloomberg reported that Illumina was in talks to buy their former spinout for up to $8 billion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Roche vaults to the front of the NL­RP3 clin­i­cal race, pay­ing $448M up­front to bag In­fla­zome

Roche is going all in on NLRP3.

The pharma giant is putting down $448 million (€380 million) upfront to snatch Novartis-backed Inflazome, which makes it a clinical player in the space overnight.

Dublin and Cambridge, UK-based Inflazome is the second NLRP3-focused biotech Roche has acquired in less than two years, and although no numbers were disclosed in the Jecure buyout, this is almost certainly a much larger deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Anthony Fauci (AP Images)

A press of­fi­cer at An­tho­ny Fau­ci’s NI­AID was un­masked as a hard-right Covid troll. He just re­tired to­day

William B Crews had been a public affairs specialist at the NIH’s National Institute of Allergy and Infectious Diseases.

That ended today when he informed the agency of his decision to retire, after he was identified as the managing editor at RedState, a prominent Trump loyalist website.

Crews’ RedState duties are performed under the alias streiff. While enjoying the benefits of pseudonymity, he disparaged and worked against NIAID with an incendiary level of rhetoric in the midst of a pandemic.

#ES­MO20: Bris­tol My­ers marks Op­di­vo's sec­ond ad­ju­vant win — eye­ing a stan­dard of care gap

Moving into earlier and earlier treatment lines, Bristol Myers Squibb is reporting that adjuvant treatment with Opdivo has doubled the time that esophageal or gastroesophageal junction cancer patients stay free of disease.

With the CheckMate-577 data at ESMO, CMO Samit Hirawat said, the company believes it can change the treatment paradigm.

While a quarter to 30% of patients typically achieve a complete response following chemoradiation therapy and surgery, the rest do not, said Ronan Kelly of Baylor University Medical Center. The recurrence rate is also high within the first year, Hirawat added.

Donald Trump, AP

Covid-19 roundup: Trump sug­gests Pfiz­er vac­cine could be first ap­proved; VBI Vac­cines inks de­vel­op­ment deal with Cana­da

President Donald Trump commented Monday morning that Pfizer’s Covid-19 vaccine candidate could be the first to win approval by regulators.

During an interview on a Fox News’ morning show, the president said Pfizer was doing “very well” when asked which candidate could be approved, according to a Reuters report. He added that J&J could follow up afterward, saying “they’ll probably be a little later.”